ENTITY

Ascentage Pharma Group Corp (6855 HK)

35

Analysis

Health Care • China

Ascentage Pharma Group International operates as a clinical-stage biotechnology company. The Company develops novel therapies for cancers, hepatitis B virus, age-related diseases, and more. Ascentage Pharma Group International conducts businesses in China, the United States, and other countries.

more

Refresh

Exchange Announcement • 17 Nov 2024 18:13

Voluntary Announcement - Ascentage Pharma Announces A New Drug Application For Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted And Recommended Priority Review Designation By Cde Of China'S Nmpa

Exchange Announcement • 06 Nov 2024 08:17

Voluntary Announcement - Ascentage Pharma To Present Results From Multiple Clinical Studies Of Olverembatinib, Lisaftoclax, Apg-5918 And Apg-2449 At The 2024 American Society Of Hematology (Ash) Annual Meeting, Two Of Which Have Been Selected For Oral Reports

Exchange Announcement • 25 Oct 2024 07:54

Supplemental Announcement - (1) Cancellation Of The Original Grant Of Awards Under The 2021 Rsu Scheme And The 2022 Rsu Scheme; And (2) Reallocation Of Underlying Shares Of The Original Grant Of Awards And Re-Grant Of Awards Under The 2018 Rsu Scheme And The 2022 Rsu Scheme

Exchange Announcement • 08 Oct 2024 07:30

Ascentage Pharma Received Cde Clearance For Registrational Phase Iii Studies Of Apg-2449 For Treatment Of Patients With Nsclc

Exchange Announcement • 01 Oct 2024 18:29

Interim Report 2024

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5

x